Chembio Diagnostics Reports Third Quarter Financial Results

Conference Call and Webcast Today at 10:00 a.m. Eastern Time

MEDFORD, NY, November 12, 2015 -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care ("POC") diagnostic tests for infectious diseases, today reported financial results for the three and nine months ended September 30, 2015.

John J. Sperzel III, Chief Executive Officer, stated, "During the third quarter of 2015, Chembio continued to focus on the following three business areas: Sexually Transmitted Diseases ("STD"), Fever Diseases, and Technology Collaborations. In the third quarter of 2015, the company achieved significant milestones in each of these areas, which created additional value in our products and partnerships. With respect to STD, the launch of our SURE CHECK® HIV 1/2 self-testing kits in Europe was a great success, and we have received orders that will bring our total sales of these kits to approximately $1.0 million in 2015. Concerning Fever Diseases, the Paul G. Allen Ebola Program selected DPP® as a platform for the first ever POC multiplex fever disease panel, granting Chembio $2.1 million for 12-month development of this groundbreaking test. And, in the area of Technology Collaborations, our successful feasibility work with DPP® as a platform for a specific type of cancer allowed us to advance to the development stage with additional committed funding from our DPP® Cancer partner."

Mr. Sperzel continued, "These recent successes drive us to reaffirm our commitment to innovation, the development of new products, and the optimization of existing products. Our successful feasibility work on a DPP® Malaria Assay allowed us to achieve a greater than 10-fold increase in sensitivity as compared to the current market-leading POC malaria test, and we plan to commercialize multiple DPP® Malaria Assays to identify plasmodium falciparum and other plasmodium infections. We also launched the DPP® Micro Reader, which we believe offers important data capture, transmission and storage capabilities. With growing validation from leading healthcare groups and our internal development successes, we believe we are well positioned to expand our product lines, our brands, and our markets worldwide."

Addressing the company's financial results, Mr. Sperzel commented, "During the third quarter of 2015, Chembio recorded $6.9 million in revenue – the highest quarterly revenue recorded in 2015. Revenues from our U.S. HIV product sales during the quarter increased by 21% as compared to the third quarter of 2014 and increased by 34% as compared to the second quarter of 2015. It is also important to note that sales of our DPP® Ebola Assay to the Centers for Disease Control and Prevention (CDC) for field testing in West Africa generated revenues of $150,000 in the third quarter, with orders for our DPP® Malaria-Ebola and DPP® Ebola Assays of $900,000 for the fourth quarter. We are also pleased to report that in the first half of the fourth quarter, we received payments of $6.8 million from our customer in Brazil and the account receivable for this customer is current as of November 11, 2015. We also have indication that the Ministry of Health in Brazil anticipates product demand in 2016 that leads us to believe Brazil will continue to be a strong market for Chembio.

Financial information comparing the 2015 third quarter to the 2014 third quarter:

•	Total revenues of $6.89 million, compared with $7.31 million (a decrease of 5.8%).

•	Product sales of $6.21 million, compared with $7.25 million (a decrease of 14.3%).

•	Operating loss of $579,000, compared with operating loss of $262,000.

•	Net loss of $437,000, or $0.05 per diluted share, compared with net loss of $271,000, or $0.03 per diluted share.

Financial information comparing the first nine months of 2015 to the first nine months of 2014:

•	Total revenues of $19.83 million, compared with $20.55 million (a decrease of 3.5%).

•	Product sales of $18.15 million, compared with $19.40 million (a decrease of 6.5%).

•	Operating loss of $2,352,000, compared with operating loss of $878,000.

•	Net loss of $1,748,000, or $0.18 per diluted share, compared with net loss of $641,000, or $0.07 per diluted share.

Additional Financial Information

Third Quarter:

Total revenues for the third quarter of 2015 of $6.89 million were down 5.8% compared with total revenues of $7.31 million in the prior-year period. Product sales in the 2015 third quarter of $6.21 million were down 14.3% compared with product sales of $7.25 million in the prior-year period. R&D milestone, and grant and royalty revenues for the three months ended September 30, 2015 increased to $678,000 from $66,000 in the prior-year period.

Gross margin dollars for the 2015 third quarter increased 9.8% to $2.91 million compared with $2.65 million for the prior-year period, due primarily to the increase in non-product revenues. The amount of product gross margin dollars for the third quarter of 2015 decreased 13.6% to $2.23 million, from $2.58 million in the prior-year period.

R&D expenses in the third quarter of 2015 were $1.57 million, compared with $.97 million in the prior-year period. This increase is due primarily to increased R&D activities for projects and grants. Some projects are on a milestone basis for which revenue cannot be recognized until the milestone is achieved, while expenses to reach that milestone are expensed in the period incurred.

Selling, general and administrative expenses in the third quarter of 2015 decreased to $1.92 million from $1.94 million in the prior-year period, largely due to decreased consulting, stock-based compensation and marketing material expenses, partially offset by increases in staffing, wages and related costs, and increased travel expenses (related to our commercialization efforts).

Operating loss for the third quarter of 2015 was $579,000, compared with an operating loss of $262,000 for the prior-year period.

Net loss for the third quarter of 2015 was $437,000, or $0.05 per diluted share, compared with net loss of $271,000, or $0.03 per diluted share, for the prior-year period.

First Nine Months:

Total revenues for the first nine months of 2015 of $19.83 million were down 3.5% compared with total revenues of $20.55 million in the prior-year period. Product sales in the 2015 first nine months of $18.15 million were down 6.5% compared with product sales of $19.40 million in the prior-year period. R&D milestone, and grant and royalty revenues for the nine months ended September 30, 2015 increased to $1.69 million from $1.15 million in the prior-year period.

Gross margin dollars for the 2015 first nine months increased 9.0% to $8.62 million compared with $7.91 million for the prior-year period, due primarily to the increase in non-product revenues. The amount of product gross margin for the first nine months of 2015 increased 2.5% to $6.93 million, from $6.76 million in the prior-year period.

R&D expenses in the first nine months of 2015 were $4.91 million, compared with $3.44 million in the prior-year period. This increase is due primarily to increased R&D activities for projects and grants. Some projects are on a milestone basis for which revenue cannot be recognized until the milestone is achieved, while expenses to reach that milestone are expensed in the period incurred.

Selling, general and administrative expenses in the first nine months of 2015 increased to $6.06 million from $5.34 million in the prior-year period, largely due to increased commissions on sales in Brazil, increased staffing, wages and related costs, increased travel expenses (related to our commercialization efforts), and professional fees.

Operating loss for the first nine months of 2015 was $2,353,000, compared with an operating loss of $878,000 for the prior-year period.

Net loss for the first nine months of 2015 was $1,748,000, or $0.18 per diluted share, compared with net loss of $641,000, or $0.07 per diluted share, for the prior-year period.

Balance Sheet Highlights:

The Company had cash and cash equivalents of $1.10 million as of September 30, 2015, compared with $4.61 million as of December 31, 2014. The decrease was primarily due to net cash used in operating activities of $2.58 million, as well as investing activities to fund the purchase of a license and deposits on and purchase of fixed assets of $.93 million. Our accounts receivable balance as of September 30, 2015 was nearly double our historical levels. As of November 11, 2015 the customer, representing $7.9 million of the September 30, 2015 receivables has made $6.8 million in payments since the end of the third quarter of 2015. Our working capital decreased by $1.77 million during the nine months from $12.37 million to $10.60 million.

Conference Call

To participate on the conference call on November 12, 2015 at 10:00 a.m. Eastern Time, please dial (877) 407-0778 from the U.S. or (201) 689-8565 from outside the U.S. In addition, following the completion of the call, a telephone replay will be accessible until November 19, 2015 at 11:59 p.m. Eastern Time by dialing (877) 660-6853 from the U.S. or (201) 612-7415 from outside the U.S. and entering conference ID #:13623142. Those interested in listening to the conference call live via the internet may do so by visiting the Investor Relations section of Chembio's website at www.chembio.com. The conference call may also be accessed via the internet at http://www.investorcalendar.com/IC/CEPage.asp?ID=174451. An archive of the webcast will be available for 90 days on the Company's website at www.chembio.com.

About Chembio Diagnostics

Chembio Diagnostics, Inc. develops, manufactures, licenses and markets proprietary rapid diagnostic tests in the growing $8.0 billion point-of-care testing market. Chembio markets its DPP^® HIV 1/2 Assay and HIV 1/2 STAT-PAK® Assay in the U.S. and internationally. The Company's SURE CHECK^® HIV 1/2 Assay is marketed exclusively in the U.S. as Clearview^® Complete by a single entity. Outside the U.S., Chembio markets its SURE CHECK^® HIV 1/2 Assay primarily through distributors.

Chembio has developed a patented point-of-care (POC) test platform technology, the Dual Path Platform (DPP^®) technology, which has significant advantages over lateral-flow technologies. This technology is providing Chembio with a significant pipeline of business opportunities for the development and manufacture of new products.

Headquartered in Medford, NY, Chembio is licensed by the U.S. Food and Drug Administration (FDA) as well as the U.S. Department of Agriculture (USDA), and is certified for the global market under the International Standards Organization (ISO) directive 13485. Chembio Diagnostic Systems, Inc. is a wholly-owned subsidiary of Chembio Diagnostics, Inc. For more information, please visit: www.chembio.com.

Forward-Looking Statements

Statements contained herein that are not historical facts may be forward-looking statements within the meaning of the Securities Act of 1933, as amended. Forward-looking statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements, which are estimates only, reflect management's current views, are based on certain assumptions, and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to Chembio's ability to obtain additional financing and to obtain regulatory approvals in a timely manner, as well as the demand for Chembio's products. Chembio undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in Chembio's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact Chembio's success are more fully disclosed in Chembio's most recent public filings with the U.S. Securities and Exchange Commission.

(Tables to follow)

Contacts:

Chembio Diagnostics

Susan Norcott

(631) 924-1135, ext. 125

snorcott@chembio.com

Vida Strategic Partners (investor relations)

Stephanie C. Diaz

(415) 675-7401

sdiaz@vidasp.com

Investor Presentation November 2015

NASDAQ:CEMI

Rapid Tests for Earlier Treatment™™

Slide 2

Forward Looking Statements

Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of Chembio and its management. Such statements reflect management's current views, are based on certain assumptions, and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, Chembio's ability to develop, manufacture, market and finance new products and the demand for Chembio's products. Chembio undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in Chembio's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Other factors that may impact Chembio's success are more fully disclosed in Chembio's most recent public filings with the U.S. Securities and Exchange Commission.

Slide 3

Investment Highlights

§	A global leader in point-of-care (POC) infectious disease

–	Sales in 40+ countries, including United States

§	Revenue growth

–	15% CAGR over last five years (2010-2014)

§	Groundbreaking DPP^® technology platform

–	Superior sensitivity and specificity vs lateral flow technology

–	Multiple tests from a single oral fluid or blood sample

–	DPP^® revenue growth of 137% in 2014 as compared to 2013

§	Robust pipeline of new DPP^® POC assays in development

–	DPP^® HIV-Syphilis Combination Assay (U.S. version)

–	DPP^® Fever Assays (Malaria, Dengue Fever, Ebola)

–	DPP^® Technology Collaboration (Traumatic Brain Injury and Cancer)

§	Multiple high-value collaborations

–	Paul G. Allen Ebola Program: Fever Panel

–	Centers for Disease Control & Prevention (CDC): Malaria, Ebola, Flu Immunostatus

- Perseus Science Group LLC: Traumatic Brain Injury

Slide 4

Chembio's Dual Path Platform (DPP^®) Technology
Next-Generation Point-of-Care Technology Platform

§	Patented POC technology platform

§	Improved sensitivity vs. lateral flow technology

§	Multiple test results from a single patient sample

§	Adapts to multiple sample types (blood, oral fluid)

§	Application across a range of diseases and markets

§	Unique sample collection device: Sampletainer^®

See graphics

Slide 5

Chembio's Dual Path Platform (DPP^®) Technology

Leveraging Our Technology Platform to Enter New Markets

Three areas of Strategic Focus:

·	STD Business

·	Fever Portfolio

·	Technology Collaborations

DPP® Technology Platform

Slide 6

HIV Continues to be a Global Health Crisis Syphilis and HIV-Syphilis Co-Infection are Increasing

United States (HIV)

·	~ 1.2 million living with HIV/AIDS

·	~ 50,000 new HIV infections/year

·	1 in 8 unaware of HIV infection

Global (HIV)

·	35.2 million living with HIV/AIDS (2012)

·	1.6 million died of AIDS-related illnesses (2012)

United States (SYP)

·	~56,000 new infections (2013)

Global (SYP)

·	12 million new infections/year

"Over the past decade, the number of people living with HIV has increased, while the annual number of new HIV infections has remained relatively stable." -CDC

"About 30% of pregnant women with syphilis will give birth to a dead baby (stillbirth), and another 30% to a live baby with congenital syphilis, a condition with a mortality of up to 50%" -WHO

Slide 7

Product Portfolio: Sexually Transmitted Diseases

·	DPP® HIV-Syphilis Combination

·	DPP® HIV 1/2 Blood or Oral Fluid

·	HIV 1/2 STAT-PAK®

·	SURE CHECK® HIV 1/2

See graphics

Slide 8

Chembio Lateral Flow HIV Tests, Foundational HIV Product Suite

Product Features & Benefits

·	FDA (PMA) approved, CLIA-waived

·	CE marked, WHO pre-qualified

·	2.5 - 5.0 μL blood sample

·	15 - 20 minute test time

·	Specificity: 99.9%, Sensitivity: 99.7%

Commercialization

·	High quality brands, marketed globally since 2007

·	Sold to Public Health Clinics, POLs, Hospitals, Self Test (EU)

·	Certain Distribution Partners (US): Fisher, McKesson/PSS, H. Schein, Medline

See graphics

Slide 9

Chembio DPP^® HIV and DPP^® HIV-SYP Combo Tests
Addressing a Significant and Growing Need

§	DPP^® HIV-Syphilis Combo Assay

–	First to market with POC HIV-Syphilis combo assay

–	First to receive USAID and ANVISA (Brazil) approved

–	Successfully launched in Mexico

–	Global screening opportunity:

•	Pregnant women

•	MSM (up to 70% HIV-Syphilis co-infection)

·	DPP^® HIV 1/2 Assay

–	FDA-approved and CLIA-waived (blood and oral fluid)

–	Superior performance (sensitivity) vs. competitors

–	Patented SampleTainer® Sample Collection System

–	U.S. Launch – Q4 2014

See graphics

Slide 10

DPP^® STD - Product Development
Strengthening our STD Portfolio: HIV & Syphilis

§	DPP^® HIV-Syphilis Assay (U.S. market)

–	Next Generation DPP^® HIV-Syphilis Combo Assay for detection of HIV and Syphilis antibodies

–	Expect clinical trials to begin Q4 2015

•	Number of patients: 1200

•	Duration: 6-9 months

•	Cost: $1.0 - $1.5MM

DPP^® HIV Ab/Ag Assay

–	Next Generation DPP^® HIV Assay for the detection of HIV antibodies and antigens

–	Advancing through internal stage gate product development process

Slide 11

Chembio's Dual Path Platform (DPP^®) Technology Leveraging Our Technology Platform to Enter New Markets

Three areas of Strategic Focus:

·	STD Business

·	Fever Portfolio

·	Technology Collaborations

DPP® Technology Platform

Slide 12

Fever Diseases - A Growing Global Concern
Malaria, Dengue Fever, Ebola

Malaria

·	~198 million infections/year(2013)

·	~584 thousand deaths/year (2013)

Dengue Fever

·	~100 million infections/year (2013)

·	40% of world population at risk from Dengue (2013)

Ebola

·	~28,000 infections (2014-2015)

·	~11,000 deaths (2014-2015)

"Early diagnosis and treatment of malaria reduces disease and prevents deaths. It also contributes to reducing malaria transmission. WHO recommends that all cases of suspected malaria be confirmed using parasite-based diagnostic testing (either microscopy or rapid diagnostic test) before administering treatment" -WHO

Slide 13

DPP^® Fever - Product Development
Partnering with World Leading Organizations

DPP® Fever Panel

Description: DPP® Fever Panel Assay

Collaborator: Paul G. Allen Ebola Program

DPP® Malaria-Ebola

Description: Dpp® Malaria-Ebola Assay

Collaborator: CDC

DPP® Dengue Fever

Description: DPP® Dengue Fever Assay

Collaborator: Undisclosed

DPP® Ebola

Description: DPP® Ebola Assay

Collaborator: CDC

Slide 14

Case Study: Fever Diseases
Malaria, Dengue Fever, Ebola

PROBLEM:

Multiple diseases present with similar symptoms (e.g. fever)

Lack of sensitivity and/or specificity in current POC tests

Need to detect asymptomatic patients to prevent spread of disease

Certain diseases (e.g. Malaria) have multiple strains

SOLUTION: Chembio's DPP^® Platform

Can test for multiple markers with a single blood or oral fluid sample

POC test with superior sensitivity – allows healthcare workers to identify asymptomatic patients

Allows diagnosis to facilitate proper treatment

COMMERCIALIZATION SCENARIO:

Products developed with funding from partners: Paul G. Allen Ebola Program; CDC

Chembio retains global commercialization rights

Slide 15

Chembio's Dual Path Platform (DPP^®) Technology Leveraging Our Technology Platform to Enter New Markets

Three areas of Strategic Focus:

·	STD Business

·	Fever Portfolio

·	Technology Collaborations

DPP® Technology Platform

Slide 16

Established DPP^® Technology Collaborations
Building Both STD and Non-STD Businesses

opTricon (Germany)

·	DPP® Micro Reader designed specifically to complement Chembio's patented DPP® technology

Bio-Rad Laboratories, Inc. (NYSE: BIO)

–	DPP^® used for Bio-Rad's Geenius™ HIV 1/2 Confirmatory Assay

Oswaldo Cruz Foundation (Brazil)

–	Five DPP^® Products Currently Being Sold to Ministry of Health

RVR (Malaysia)

–	License, Technical Transfer, Contract Manufacturing, Distribution (planned)

Slide 17

DPP^® Technology - Collaborations
Focused on Specific Product Development Opportunities

DPP® Flu Immunostatus

Description: DPP^® Multiplex Assay to monitor seasonal and pandemic flu

Collaborator: Centers for Disease Control & Prevention (contractor)

DPP® Traumatic Brain Injury

Description: DPP^® Assay to identify Traumatic Brain Injury

Collaborator: Perseus Science Group LLC

DPP® Cancer (Specific Form)

Description: DPP^® Assay to identify a specific form of cancer

Collaborator: Undisclosed

DPP® Hepatitis C

Description: DPP^® Assay to identify Hepatitis C

Collaborator: Seeking Partner

Slide 18

Case Study: Cancer
Allows Early Detection and Monitoring

PROBLEM:

Survival can be dependent upon early detection

Cancer biomarkers can be very difficult to detect at low levels

Requires platform with increased sensitivity and quantification

SOLUTION: Chembio's DPP^® Platform

POC test with superior specificity and sensitivity

Allows early intervention and potentially improved opportunity for survival by detecting a specific cancer biomarker at low levels

ANTICIPATED COMMERCIALIZATION SCENARIO:

Product developed with funding from an undisclosed partner

Chembio gains license and/or royalty opportunity

Slide 19

Manufacturing Capabilities

United States (Chembio)

§	High volume manufacturing capabilities

–	20MM+ tests annually

§	60,000 sq. ft. leased facilities

–	Medford, NY and Holbrook, NY

§	Robust quality management system

–	Full compliance with regulatory requirements (FDA, USDA, WHO, ISO)

–	Expertise in manufacturing scale up, process validation and cGMP

§	Number of employees: ~150

Malaysia (RVR)

§	Completed license and technology transfer

§	Contract manufacturing planned: Q4 2015

§	Distribution of Chembio's products into Malaysia and other select Asian markets

–	Launch anticipated Q4 2015

§	Plan to manufacture certain Chembio-branded products for Chembio distribution

See graphics

Slide 20

Selected Financial Highlights

Nine Months Ended (in 000's)

	September 30, 2015			September 30, 2014
Net Product Revenues	$	18,146		$	19,400
Total Revenues	$	19,835		$	20,550
Gross Margin	$	8,616		$	7,906
Loss from Operations	$	(2,353	)	$	(878	)
Net Loss	$	(1,748	)	$	(641	)
Cash (as of end of period)	$	1,102		$	3,673

Note: Accounts receivable as of 9/30/14 was $8,316 compared to 9/30/15 of $9,515

(collected $6.8MM from Brazilian customer from 9/30/15 – 11/5/15)

Slide 21

Executive Leadership Team

Executive: John J. Sperzel III, President &CEO

Previous Experience: 2011-2013, President and CEO of ITC.; 1987-2011 Axis-Shield, Bayer Diagnostics, Instrumentation Laboratory and Boehringer Mannheim

Executive: Richard Larkin, CPA Chief Financial Officer

Previous Experience: 2000-2003 CFO of Visual Technology Group; 1987-2000 CFO of Protex International Corp.

Executive: Sharon Klugewicz, M.S. Chief Operating Officer

Previous Experience: 2009-2012, Sr. VP Scientific & Laboratory Services of Pall Corporation; 1991-2009 Pall Corporation

Executive: Javan Esfandiari, M.S. Chief Science and Technology Officer

Previous Experience: 1997-2000, Co-founder of Sinovus Biotech AB (Sweden), acquired by Chembio in 2000; 1993-1997 R&D Director On-Site Biotech

Executive: Thomas Ippolito, VP Regulatory & Clinical Affairs

Previous Experience: 2000-2005, VP Quality & Regulatory of Biospecific Technologies Corp.; 1984-2000 United Biomedical Inc., Analytab Products Inc. and Eastern Long Island Hospital

Executive: Michael Steele, VP Sales, Marketing and Business Development

Previous Experience: 2008-2011, VP Business Development of SeraCare Life Sciences; 1992-2008 Corautus Genetics, Life Therapeutics and Serologicals, Inc.

Executive: Paul Lambotte, Ph.D, VP Product Development

Previous Experience: 2009 – 2014, President of PLC Inc.; 2009 – 2012 Chief Science Officer of Axxin Pty Ltd.; 2000-2009, VP of R&D and Business Development of Quidel, Inc.

Slide 22

2015 Milestones – Achieved and Anticipated

§	Acquired full rights to SURE CHECK^® HIV 1/2 Assay

–	SDS; signed January 2015 to be effective June 1, 2016

§	Signed Agreement to develop DPP^® Brain Injury Assay

–	Perseus Science; January 2015

§	Received ANVISA approval for DPP^® HIV-Syphilis Assay

–	Brazil; February 2015

§	Initiated field testing of DPP^® Ebola Assay in West Africa

–	CDC; June 2015

§	Submitted application for Ebola Emergence Use Authorization

–	Food & Drug Administration (FDA); August 2015

§	Awarded Grant to Develop Multiplex Test for Febrile Illnesses

–	Paul G. Allen Ebola Program; October 2015

§	Signed agreement to launch the DPP® Micro Reader

–	opTricon; October 2015

§	Initiate DPP^® HIV-SYP Clinical Trial: Q4 2015

Slide 23

Investment Highlights

§	A global leader in point-of-care (POC) infectious disease

–	Sales in 40+ countries, including United States

§	Revenue growth

–	15% CAGR over last five years (2010-2014)

§	Groundbreaking DPP^® technology platform

–	Superior sensitivity and specificity vs lateral flow technology

–	Multiple tests from a single oral fluid or blood sample

–	DPP^® revenue growth of 137% in 2014 as compared to 2013

§	Robust pipeline of new DPP^® POC assays in development

–	DPP^® HIV-Syphilis Combination Assay (U.S. version)

–	DPP^® Fever Assays (Malaria, Dengue Fever, Ebola)

–	DPP^® Technology Collaboration (Traumatic Brain Injury and Cancer)

§	Multiple high-value collaborations

–	Paul G. Allen Ebola Program: Fever Panel

–	Centers for Disease Control & Prevention (CDC): Malaria, Ebola, Flu Immunostatus

- Perseus Science Group LLC: Traumatic Brain Injury

Nevada	0-30379	88-0425691
(State or other jurisdiction	(Commission File Number)	(IRS Employer
of Incorporation)		Identification Number)
	3661 Horseblock Road
	Medford, NY 11763
	(Address of principal executive offices)
	631-924-1135
	(Registrant's Telephone Number)

99.1	Press Release entitled "Chembio Diagnostics Reports Third Quarter 2015 Financial Results" dated November 12, 2015
99.2	Presentation entitled "Investor Presentation November 2015" dated November 12, 2015
99.3	Investor Fact Sheet posted to the company website dated November 12, 2015

Exhibit Number	Description
99.1	Press Release entitled "Chembio Diagnostics Reports Third Quarter 2015 Financial Results" dated November 12, 2015
99.2	Presentation entitled "Investor Presentation November 2015" dated November 12, 2015
99.3	Investor Fact Sheet posted to the company website dated November 12, 2015

Chembio Diagnostics, Inc.	Investor Relations	Company Contact
3661 Horseblock Road	Vida Strategic Partners	Susan Norcott
Medford, NY 11763	Stephanie C. Diaz	631-924-1135 x125
Ph. 631-924-1135	(415) 675-7401	snorcott@chembio.com
Fax 631-924-2065	sdiaz@vidasp.com
www.chembio.com